Laurus Labs Limited

rs,

January 30, 2023 To To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 The Listing Department National Stock Exchange of Indi

₹ 4,660

estor Presentation | July 27, 2022 9M/FY23 – Overview Strong YTD operational results Revenues ₹ 4,660 Cr ▲33% EBITDA ₹ 1,307 Cr ▲ 26% Summary 9M/FY23 Consolidated Financials 9M/FY23 9M/FY22 Y-o

33%

tation | July 27, 2022 9M/FY23 – Overview Strong YTD operational results Revenues ₹ 4,660 Cr ▲33% EBITDA ₹ 1,307 Cr ▲ 26% Summary 9M/FY23 Consolidated Financials 9M/FY23 9M/FY22 Y-o-Y [₹C

₹ 1,307

27, 2022 9M/FY23 – Overview Strong YTD operational results Revenues ₹ 4,660 Cr ▲33% EBITDA ₹ 1,307 Cr ▲ 26% Summary 9M/FY23 Consolidated Financials 9M/FY23 9M/FY22 Y-o-Y [₹Crore] Revenues G

26%

FY23 – Overview Strong YTD operational results Revenues ₹ 4,660 Cr ▲33% EBITDA ₹ 1,307 Cr ▲ 26% Summary 9M/FY23 Consolidated Financials 9M/FY23 9M/FY22 Y-o-Y [₹Crore] Revenues Gross Mar

55.4%

22 Y-o-Y [₹Crore] Revenues Gross Margins EBITDA % to Revenues PBT Net Profit EPS 4,660 55.4% 1,307 28.0% 962 687 12.7 3,511 57.0% 1,038 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex

28.0%

rore] Revenues Gross Margins EBITDA % to Revenues PBT Net Profit EPS 4,660 55.4% 1,307 28.0% 962 687 12.7 3,511 57.0% 1,038 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex Net Debt-to-E

57.0%

s EBITDA % to Revenues PBT Net Profit EPS 4,660 55.4% 1,307 28.0% 962 687 12.7 3,511 57.0% 1,038 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex Net Debt-to-EBITDA 612 1.3X 770 1.3x

29.6%

o Revenues PBT Net Profit EPS 4,660 55.4% 1,307 28.0% 962 687 12.7 3,511 57.0% 1,038 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex Net Debt-to-EBITDA 612 1.3X 770 1.3x ROCE 25.5% 2

1.3X

2.7 3,511 57.0% 1,038 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex Net Debt-to-EBITDA 612 1.3X 770 1.3x ROCE 25.5% 25.5% 33% -160bps 26% -160bps 23% 15% 14% Y-o-Y -21% - - 5 La

1.3x

57.0% 1,038 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex Net Debt-to-EBITDA 612 1.3X 770 1.3x ROCE 25.5% 25.5% 33% -160bps 26% -160bps 23% 15% 14% Y-o-Y -21% - - 5 Laurus Q3 & 9

25.5%

8 29.6% 782 597 11.1 9M/FY23 9M/FY22 Capex Net Debt-to-EBITDA 612 1.3X 770 1.3x ROCE 25.5% 25.5% 33% -160bps 26% -160bps 23% 15% 14% Y-o-Y -21% - - 5 Laurus Q3 & 9M FY2023 Inve

New capabilities added

1

New capabilities added

Recombinant Proteins (FY21) CAR-T Cell therapy (FY22) FY 2025/26 Goal Over 25% revenues from Synthesis Continuous Investment in manufacturing asset, Integrated approach across portfolio, Strong quality and leadership team * Adjusting for exceptional revenues in Hep C segment, ARV: Anti-Retroviral 24 Laurus Q3 & 9M FY2023 Investor Presentation | January 30, 2023 ARV api *80%Onco & Other APIs, 16%Synthesis, 19%FDF, 38%ARV apis, 25%Bio, 2% Outlook FY2023 & Ahead Business Segments Business Segments Growth Outlook Formulations  Consolidate market share in ARVs despite pricing challenge  Niche product pipeline for the developed markets supported by in-house API strength  Strong DM pipeline >US$40bn mkt opportunity; Diabetic & CV portfolio monetization  Brownfield Scale up API demand based capacity expansion  Enhance positioning on HP APIs & Scaling up of Anti-diabetic, CV & PPI portfolio supported by  Maintain ARV API leadership position in current product line and increase developed m